Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 22,444 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pathological Processes Clear all
Active, not recruiting Not applicable Interventional

Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

NCT06735534
View directory record Official record
Conditions
Persistent Atrial Fibrillation
Interventions
FARAPULSE™ Pulsed Field Ablation System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
33
States / cities
Mobile, Alabama • Jonesboro, Arkansas • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 22, 2026, 4:30 AM EDT
Terminated Phase 2 Interventional Results available

Dose Finding Posterolateral Thoracotomy Study

NCT00807209
View directory record Official record
Conditions
Postoperative Pain
Interventions
Low Dose SKY0402, High Dose SKY0402, Placebo, Fentanyl via PCA, Bupivacaine via epidural
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Pasadena, California • Orlando, Florida • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 15, 2012 · Synced Oct 22, 2026, 4:30 AM EDT
Completed Not applicable Interventional Results available

Enhanced Protein-Energy Provision Via the Enteral Route in Critically Ill Patients

NCT01167595
View directory record Official record
Conditions
Critically Ill
Interventions
PEP uP Protocol
Other
Lead sponsor
Clinical Evaluation Research Unit at Kingston General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,059 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
9
States / cities
Phoenix, Arizona • Loveland, Colorado • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 22, 2026, 4:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Regional Fat Depots and Insulin Resistance

NCT01336777
View directory record Official record
Conditions
Obesity, Insulin Resistance, Diabetes Mellitus Type 2
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
39 Years to 65 Years
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 22, 2026, 4:30 AM EDT
Recruiting Phase 1 Interventional

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

NCT06586957
View directory record Official record
Conditions
Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Metastatic Ovarian Carcinoma, Endometrial Neoplasms, Endometrial Diseases, Metastatic Endometrial Cancer, Triple Negative Breast Cancer, Metastatic Endometrial Carcinoma, Advanced Endometrial Carcinoma, Advanced Ovarian Carcinoma, Gastric Cancer, Advanced Gastric Carcinoma, Metastatic Gastric Cancer, Metastatic Gastric Carcinoma, Small Cell Lung Cancer, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms, Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, CCNE1 Amplification, Hormone Receptor Negative Breast Carcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Progesterone-receptor-positive Breast Cancer
Interventions
NKT3964, Paclitaxel, Doxorubicin
Drug
Lead sponsor
NiKang Therapeutics, Inc.
Industry
Eligibility
19 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
19
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 4:30 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

NCT07128381
View directory record Official record
Conditions
Myelofibrosis (MF), Chronic Myelomonocytic Leukemia (CMML)
Interventions
Axatilimab (SNDX-6352), Ruxolitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 22, 2026, 4:30 AM EDT
Completed No phase listed Observational

Using MRI to Observe Lung Changes in Infants With CF Compared to Infants Without CF

NCT01832519
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Months to 52 Months
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Oct 22, 2026, 4:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Barbed Suture for Hysterotomy Closure During Cesarean Section

NCT04622267
View directory record Official record
Conditions
Hysterotomy
Interventions
Barbed suture, Standard antimicrobial suture
Device · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 22, 2026, 4:30 AM EDT
Completed Phase 1 Interventional

A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors

NCT01608867
View directory record Official record
Conditions
Solid Tumors
Interventions
OMP-54F28
Biological
Lead sponsor
OncoMed Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Scottsdale, Arizona • Aurora, Colorado • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 22, 2026, 4:30 AM EDT
Not listed No phase listed Observational

Platelet Modulation: A Study of Angiogenic and Coagulation Proteins in Patients With Cancer

NCT01148407
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 22, 2011 · Synced Oct 22, 2026, 4:30 AM EDT
Completed Phase 4 Interventional Results available

Effect of Methamphetamine on Residual Latent HIV Disease Study

NCT03825536
View directory record Official record
Conditions
HIV-1-infection, Methamphetamine-dependence
Interventions
Oral Methamphetamine, Placebo oral capsule
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 22, 2026, 4:30 AM EDT
Completed No phase listed Observational

A Retrospective Analysis of the Use of ACE-inhibitors and Angiotensin Receptor Blockers

NCT00321945
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
ACE-Inhibitors and Angiotensin Receptor Blockers
Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 27, 2013 · Synced Oct 22, 2026, 4:30 AM EDT
Completed Not applicable Interventional

Fish Oil in Total Hip Replacement Randomized Clinical Trial

NCT04360239
View directory record Official record
Conditions
Total Hip Arthroplasty
Interventions
Fish Oil
Dietary Supplement
Lead sponsor
Jeffrey L Stimac MD
Other
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 22, 2026, 4:30 AM EDT
Recruiting Phase 2 Interventional

Daridorexant to Prevent Post-cardiotomy Delirium

NCT07217912
View directory record Official record
Conditions
Postoperative Cognitive Decline, Postoperative Delirium
Interventions
Daridorexant 50 mg, Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 22, 2026, 4:30 AM EDT
Completed Phase 3 Interventional Results available

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation

NCT00116428
View directory record Official record
Conditions
Heart Diseases, Arrhythmia, Atrial Fibrillation
Interventions
NAVISTAR® THERMOCOOL® Catheter, Antiarrhythmic drug
Device · Drug
Lead sponsor
Biosense Webster, Inc.
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
13
States / cities
Greenbrae, California • Orlando, Florida • Maywood, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Oct 22, 2026, 4:30 AM EDT
Completed Phase 3 Interventional Results available

Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation

NCT02132767
View directory record Official record
Conditions
Postoperative Atrial Fibrillation
Interventions
Amiodarone, DC-cardioversion, Rate Control
Drug · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 22, 2026, 4:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of the Vaginal Gel PRO 2000/5

NCT00006207
View directory record Official record
Conditions
HIV Infections
Interventions
PRO 2000
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Oct 22, 2026, 4:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nerve Damage in Patients With HIV Infection Who Have Been Treated With Anti-HIV Drugs

NCT00017771
View directory record Official record
Conditions
HIV Infections, Peripheral Nervous System Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Oct 22, 2026, 4:30 AM EDT
Completed No phase listed Observational

Community Based Self Management of COPD Facilitated by a Palliative Care Team:Impact on Health Care Utilization and QOL

NCT00648609
View directory record Official record
Conditions
Pulmonary Disease Chronic Obstructive
Interventions
Palliative home care in advanced COPD, Standard of care
Other
Lead sponsor
Essentia Health
Other
Eligibility
60 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 20, 2011 · Synced Oct 22, 2026, 4:30 AM EDT
Not listed Phase 4 Interventional

Rate Control in Atrial Fibrillation

NCT02251509
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Carvedilol, Metoprolol tartrate
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 22, 2026, 4:30 AM EDT
Completed Phase 1 Interventional

Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma

NCT01567709
View directory record Official record
Conditions
Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Chronic Lymphocytic Leukemia, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Hepatosplenic T-Cell Lymphoma, Intraocular Lymphoma, Lymphomatous Involvement of Non-Cutaneous Extranodal Site, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Nodal Marginal Zone Lymphoma, Primary Cutaneous B-Cell Non-Hodgkin Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Small Intestinal Lymphoma, Splenic Marginal Zone Lymphoma, T-Cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Alisertib, Laboratory Biomarker Analysis, Pharmacological Study, Vorinostat
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
5
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Oct 22, 2026, 4:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Pilot Study of Minocycline in Intracerebral Hemorrhage Patients

NCT01805895
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Minocycline
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 22, 2026, 4:30 AM EDT
Terminated Phase 1 Interventional

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

NCT02313012
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
CC-90003
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Los Angeles, California • New Haven, Connecticut • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 22, 2026, 4:30 AM EDT
Completed Not applicable Interventional Results available

Adaptive CRT Effect on Electrical Dyssynchrony

NCT02543281
View directory record Official record
Conditions
Cardiomyopathy, Heart Failure, Left Bundle Branch Block
Interventions
Adaptive cardiac resynchronization therapy, Conventional Cardiac Resynchronization Therapy
Device
Lead sponsor
Larisa Tereshchenko
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 22, 2026, 4:30 AM EDT